샘플 요청 목록

 카트 문의
시장보고서
상품코드
1793922

세계의 상기도 감염 치료 시장

Upper Respiratory Tract Infection Treatment
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 372 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 상기도 감염 치료 시장은 2030년까지 149억 달러에 달할 전망

2024년에 128억 달러로 추정되는 세계의 상기도 감염 치료 시장은 분석 기간인 2024-2030년에 CAGR 2.6%로 성장하며, 2030년에는 149억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 항생제는 CAGR 3.4%를 기록하며, 분석 기간 종료시에는 82억 달러에 달할 것으로 예측됩니다. 비스테로이드성 항염증약·비강 충혈 제거약 부문의 성장률은 분석 기간 중 CAGR 1.6%로 추정됩니다.

미국 시장은 추정 35억 달러, 중국은 CAGR 5.2%로 성장 예측

미국의 상기도 감염 치료 시장은 2024년에는 35억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 29억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 5.2%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 0.9%와 2.0%로 예측됩니다. 유럽에서는 독일이 CAGR 1.4%로 성장할 것으로 예측됩니다.

세계의 상기도 감염 치료 시장 - 주요 동향과 촉진요인 정리

상기도 감염 치료가 공중보건의 우선순위가 되는 이유는 무엇인가?

감기, 인두염, 부비동염, 후두염, 편도선염 등의 질병을 포함한 상기도 감염(UTI)은 전 세계에서 가장 광범위한 건강 문제 중 하나이며 모든 연령대의 사람들에게 영향을 미치고 있습니다. 이러한 감염은 주로 바이러스성 감염이 주를 이루지만, 세균성 감염도 상당 부분을 차지하며, 특히 중증화되거나 장기화되는 경우가 많습니다. 요로결석은 자연 치유되는 경우가 많음에도 불구하고 높은 이환율, 경제적 부담, 관리 미흡시 합병증 발생 가능성으로 인해 공중보건학적으로 큰 문제가 되고 있습니다. 특히 학교, 직장, 대중교통과 같이 인구 밀집도가 높은 환경에서는 감염이 용이하므로 일년 내내 항상 존재하며, 추운 계절에 계절적으로 최고조에 달할 전망입니다. 치료의 관점에서 볼 때, 요로결석은 전 세계에서 외래 진료와 처방전 없이 구입할 수 있는 약품의 대부분을 차지합니다. 또한 요로결석은 불필요한 항생제 처방의 주요 원인 중 하나이며, 항균제 내성 문제를 야기하는 주요 원인 중 하나입니다. 공중 보건 당국과 의료 서비스 프로바이더는 효과적인 증상 완화와 약물 치료의 현명한 사용의 균형을 맞추는 데 점점 더 많은 초점을 맞추었습니다. 이 때문에 불편함을 완화하고, 감염 기간을 단축하고, 과다 투약의 위험을 최소화할 수 있는 근거에 기반한 치료법에 대한 수요가 급증하고 있습니다. 그 결과, 요로결석 치료는 여전히 의료 시스템, 의약품 개발 기업 및 세계 보건기구의 중요한 관심사가 되고 있습니다.

진화하는 치료법과 약물 혁신은 요로결석 관리를 어떻게 변화시키고 있는가?

혁신적인 약물의 도입, 약물전달의 개선, 증거에 기반한 치료 전략의 중요성으로 인해 상기도 감염 치료의 상황은 진화하고 있습니다. 충혈제거제, 해열제, 항히스타민제, 진해제를 통한 증상 완화는 여전히 요로결석 관리의 기본이지만, 환자의 편의성과 순응도를 높이기 위해 여러 증상을 동시에 치료하는 병용요법에 대한 관심이 높아지고 있습니다. 서방형 정제, 점비제, 국소 작용하는 트로치제 등 첨단 제제의 개발로 증상 조절의 속도와 효과가 향상되고 있습니다. 세균 감염의 경우 내성균의 위험을 줄이기 위해 광범위 항생제보다 협대역 항생제가 권장되고 있습니다. 동시에 특정 바이러스 균주를 보다 효과적으로 치료하기 위해 새로운 항바이러스제, 특히 면역력이 약한 집단이나 바이러스성 인두염, 심한 감기 증상의 경우 새로운 항바이러스제를 연구하고 있습니다. 맞춤형 의료와 약물유전체학의 등장으로 개인의 유전자 프로파일과 면역 반응에 맞춘 치료의 길이 열리고 있습니다. 이와 함께 식염수 관개, 허브 추출물, 면역력 강화 영양제 등 비약물학적 치료법이 보완적인 치료법으로 인기를 끌고 있습니다. 이러한 추세는 요로결석 치료에 대한 보다 총체적이고 환자 중심의 접근 방식에 기여하고 있으며, 치료 혁신은 빠른 회복뿐만 아니라 부작용을 최소화하고 장기적인 호흡기 건강을 증진하는 데 초점을 맞추었습니다.

인구통계, 계절성, 의료 인프라가 치료 수요에 미치는 역할은?

상기도 감염 치료에 대한 수요는 인구 통계, 계절적 패턴, 적시에 치료를 제공하는 의료 시스템의 능력과 밀접한 관련이 있습니다. 어린이와 노인은 면역 체계가 상대적으로 약하거나 발달하지 않아 가장 취약한 집단으로 발병률이 높고 합병증을 유발할 가능성이 높습니다. 특히 소아 요로결석의 경우, 학교 결석과 불편함을 줄이기 위해 부모들이 신속하고 효과적인 치료법을 찾기 위해 많은 임상 진료와 투약이 이루어지고 있습니다. 마찬가지로 합병증이 있는 노인은 2차 감염 및 입원 위험이 높기 때문에 보다 신중한 치료 전략이 필요합니다. 계절성도 큰 요인 중 하나로, 실내 혼잡과 공기 순환 저하로 인해 바이러스가 급속히 확산되는 추운 시기나 우기에 감염자가 급증합니다. 기후, 인구밀도, 오염도 등 지역적 차이도 감염률과 치료법에 영향을 미칩니다. 의료 인프라는 신속한 진단, 적절한 약품의 확보, 효과적인 공중보건 메시지 전달 등 잘 갖추어진 시스템을 통해 치료의 접근성과 질에 결정적인 역할을 합니다. 이와는 대조적으로, 충분한 서비스를 받지 못하는 지역에서는 진단과 치료가 늦어지고, 질병이 장기화되거나 일반 의약품에 과도하게 의존하는 경우가 있습니다. 원격의료와 디지털 헬스 플랫폼의 통합은 특히 도시 지역에서 실제 진료소를 방문하지 않고도 보다 신속한 진료, 디지털 처방, 경과 관찰을 가능하게 함으로써 요로결석 관리 방법에도 영향을 미치고 있습니다. 이러한 인구통계학적, 구조적 요인이 각 지역의 상기도 감염 치료의 규모, 시급성, 형태를 형성하고 있습니다.

상기도 감염 치료 시장의 성장을 가속하는 주요 요인은?

상기도 감염 치료제 시장의 성장은 역학 동향, 소비자 행동, 헬스케어 혁신의 조합으로 인해 발생합니다. 가장 큰 원동력 중 하나는 전 세계에서 요로결석의 유병률이 지속적으로 높아 처방약과 일반의약품 모두에 대한 안정적이고 지속적인 수요가 확보되고 있다는 점입니다. 이러한 감염성 질환이 만연하다는 것은 치료 효과와 접근성이 조금이라도 개선된다면 큰 시장 이익으로 이어질 수 있다는 것을 의미합니다. 또 다른 주요 요인은 빠른 증상 완화 및 여러 증상에 대응하는 제형에 대한 소비자의 선호도가 높아지면서 보다 진보된 제형과 전달 형태가 개발되고 있다는 점입니다. 소매 약국 체인, E-Commerce 의약품 플랫폼, 원격의료 서비스의 확대도 소비자가 병원이나 진료소를 방문하지 않고도 쉽게 치료를 받을 수 있도록 돕고 있습니다. 항생제 오남용의 위험성에 대한 인식이 높아짐에 따라 환자와 의료 서비스 프로바이더 모두 보다 책임감 있는 치료법을 채택하고, 약초 및 동종요법과 같은 대체요법 및 지지요법에 대한 관심이 높아지고 있습니다. 또한 신흥 국가에서는 건강 보험이 보편화되면서 브랜드 의약품에 대한 접근성과 접근성이 향상되고 있습니다. 제약사들은 소아 전용 제제, 새로운 항바이러스제, 더 나은 내약성 등에 중점을 두고 요로결석 치료제 포트폴리오를 차별화하기 위해 타겟팅된 연구개발에 투자하고 있습니다. 호흡기 위생과 조기 증상 관리를 위한 공중보건 캠페인은 치료에 대한 적극적인 접근에 더욱 기여하고 있습니다. 이러한 힘의 결집으로 상기도 감염 치료 시장은 모든 연령층과 의료 시스템을 아우르는 견고하고 진화한 시장으로, 앞으로도 지속적인 혁신과 확장이 예상됩니다.

부문

유형(항생제, 비스테로이드성 소염 진통제, 기타 치료제); 유통 채널(병원 약국, 소매 약국, 온라인 약국); 효능·효과(감기, 부비강염, 인두염, 후두염)

조사 대상 기업의 예

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Chiesi Farmaceutici S.p.A.
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan(Viatris)
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Roche Holding AG
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Verona Pharma plc

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.08.28

Global Upper Respiratory Tract Infection Treatment Market to Reach US$14.9 Billion by 2030

The global market for Upper Respiratory Tract Infection Treatment estimated at US$12.8 Billion in the year 2024, is expected to reach US$14.9 Billion by 2030, growing at a CAGR of 2.6% over the analysis period 2024-2030. Antibiotics, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$8.2 Billion by the end of the analysis period. Growth in the NSAIDs & Nasal Decongestants segment is estimated at 1.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.5 Billion While China is Forecast to Grow at 5.2% CAGR

The Upper Respiratory Tract Infection Treatment market in the U.S. is estimated at US$3.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.9 Billion by the year 2030 trailing a CAGR of 5.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 2.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.4% CAGR.

Global Upper Respiratory Tract Infection Treatment Market - Key Trends & Drivers Summarized

Why Does the Treatment of Upper Respiratory Tract Infections Remain a Public Health Priority?

Upper respiratory tract infections (URTIs), which include ailments such as the common cold, pharyngitis, sinusitis, laryngitis, and tonsillitis, continue to be among the most widespread health issues globally, affecting individuals across all age groups. These infections are primarily viral in origin, though bacterial agents also contribute to a significant portion of cases, particularly in more severe or prolonged episodes. Despite being self-limiting in many instances, URTIs represent a major public health concern due to their high incidence rate, economic burden, and potential to cause complications if inadequately managed. The ease of transmission, especially in densely populated settings like schools, workplaces, and public transportation, ensures their constant presence throughout the year, with seasonal peaks in colder months. From a treatment perspective, URTIs account for a large volume of outpatient visits and over-the-counter medication purchases globally. Additionally, they are one of the leading causes of unnecessary antibiotic prescriptions, contributing to the growing challenge of antimicrobial resistance. Public health authorities and healthcare providers are increasingly focused on balancing effective symptom relief with judicious use of pharmacological therapies. This has led to a surge in demand for targeted, evidence-based treatment options that alleviate discomfort, reduce infection duration, and minimize the risk of overmedication. As a result, treatment of URTIs remains a critical area of focus for healthcare systems, pharmaceutical developers, and global health organizations.

How Are Evolving Treatment Modalities and Drug Innovations Reshaping URTI Management?

The landscape of upper respiratory tract infection treatment is evolving with the introduction of innovative drugs, improved delivery mechanisms, and a greater emphasis on evidence-based therapeutic strategies. While symptomatic relief through decongestants, antipyretics, antihistamines, and cough suppressants remains the cornerstone of URTI management, there is increasing interest in combination therapies that address multiple symptoms simultaneously to enhance patient comfort and compliance. The development of advanced formulations, such as extended-release tablets, nasal sprays, and lozenges with localized action, is improving the speed and effectiveness of symptom control. In cases involving bacterial infections, narrow-spectrum antibiotics are being promoted over broad-spectrum alternatives to reduce the risk of resistance. At the same time, novel antiviral agents are being explored to treat specific viral strains more effectively, particularly in immunocompromised populations and in cases of viral pharyngitis or severe cold symptoms. The rise of personalized medicine and pharmacogenomics is also opening the door to treatments tailored to individual genetic profiles and immune responses. In parallel, non-pharmacological options such as saline irrigation, herbal extracts, and immune-boosting nutraceuticals are gaining popularity as complementary treatments. These trends are contributing to a more holistic and patient-centered approach to URTI care, where therapeutic innovation focuses not just on rapid recovery but also on minimizing side effects and promoting long-term respiratory health.

What Role Do Demographics, Seasonality, and Healthcare Infrastructure Play in Treatment Demand?

The demand for upper respiratory tract infection treatment is closely linked to demographic profiles, seasonal patterns, and the capacity of healthcare systems to deliver timely care. Children and the elderly represent the most vulnerable groups due to their comparatively weaker or less-developed immune systems, leading to higher incidence rates and a greater likelihood of complications. Pediatric URTI cases, in particular, drive significant volumes of clinical consultations and medication use, as parents seek fast and effective remedies to reduce school absenteeism and discomfort. Similarly, elderly populations with comorbid conditions are often at greater risk of secondary infections or hospitalization, requiring more careful treatment strategies. Seasonality is another major factor, with sharp increases in cases during colder months or rainy seasons when viruses spread more rapidly due to indoor crowding and reduced air circulation. Geographic differences in climate, population density, and pollution levels also influence infection rates and treatment approaches. Healthcare infrastructure plays a decisive role in the accessibility and quality of treatment, with well-equipped systems providing rapid diagnostics, access to appropriate medications, and effective public health messaging. In contrast, underserved regions may face delays in diagnosis and treatment, leading to prolonged illness or overreliance on over-the-counter solutions. The integration of telemedicine and digital health platforms is also influencing how URTIs are managed, particularly in urban centers, by enabling faster consultations, digital prescriptions, and follow-ups without the need for physical clinic visits. These demographic and structural factors collectively shape the scale, urgency, and mode of upper respiratory infection treatment across different regions.

What Are the Key Factors Driving Growth in the Upper Respiratory Tract Infection Treatment Market?

The growth in the upper respiratory tract infection treatment market is driven by a combination of epidemiological trends, consumer behavior, and healthcare innovation. One of the foremost drivers is the consistently high global incidence of URTIs, which ensures a stable and recurring demand for both prescription and over-the-counter therapies. The widespread nature of these infections means that even modest improvements in treatment effectiveness or accessibility can translate into significant market gains. Another key factor is the increasing consumer preference for rapid relief and multi-symptom formulations, which has led to the development of more advanced combination drugs and delivery formats. The expansion of retail pharmacy chains, e-commerce drug platforms, and telehealth services is also making it easier for consumers to access treatment without visiting a hospital or clinic. Rising awareness about the risks of antibiotic misuse is encouraging both patients and providers to adopt more responsible treatment practices, which is fueling interest in alternative and supportive therapies, including herbal and homeopathic options. Additionally, the growth of health insurance coverage in emerging economies is improving affordability and access to branded medications. Pharmaceutical companies are investing in targeted R&D to differentiate their URTI portfolios, focusing on pediatric-specific formulations, new antivirals, and better drug tolerability. Public health campaigns aimed at respiratory hygiene and early symptom management are further contributing to a proactive approach to care. These converging forces are creating a robust and evolving market for upper respiratory tract infection treatment that spans all age groups and healthcare systems, ensuring ongoing innovation and expansion in the years ahead.

SCOPE OF STUDY:

The report analyzes the Upper Respiratory Tract Infection Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Antibiotics, NSAIDs & Nasal Decongestants, Other Treatments); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); Indication (Common Cold, Sinusitis, Pharyngitis, Laryngitis)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Chiesi Farmaceutici S.p.A.
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan (Viatris)
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Roche Holding AG
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Verona Pharma plc

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Upper Respiratory Tract Infection Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Viral Infections Throws the Spotlight on Rapid-Relief URTI Treatment Options
    • Post-Pandemic Awareness Spurs Demand for Early Symptom Management and Preventive Therapies
    • Here's How Growth in Self-Medication Is Driving Adoption of OTC and Herbal Remedies for URTIs
    • Antibiotic Stewardship Campaigns Strengthen the Business Case for Non-Antibiotic Treatment Alternatives
    • Increasing Preference for Symptom-Specific Combination Therapies Propels Innovation in Formulation Design
    • Telemedicine and E-Pharmacy Expansion Accelerate Access to Prescription and OTC URTI Treatments
    • Here's the Story: How Seasonal Peaks and Viral Mutation Cycles Are Reshaping Inventory and Demand Patterns
    • Growing Geriatric and Pediatric Populations Expand the Addressable Market for Age-Appropriate Treatments
    • Consumer Shift Toward Immune-Boosting Products Sustains Growth in Supplements Targeting URTI Prevention
    • Technological Advancements in Rapid Diagnostics Drive Timely and Targeted Treatment Decisions
    • Urbanization and Air Pollution Levels Generate Demand for Respiratory Relief Medications and Protectives
    • Rising Healthcare Access in Developing Regions Fuels Market Penetration of Generic URTI Therapeutics
    • Cross-Border E-Commerce Trends Drive Global Reach of OTC and Natural URTI Remedies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Upper Respiratory Tract Infection Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Upper Respiratory Tract Infection Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for NSAIDs & Nasal Decongestants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for NSAIDs & Nasal Decongestants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for NSAIDs & Nasal Decongestants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Laryngitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Laryngitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Laryngitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Common Cold by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Common Cold by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Common Cold by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Sinusitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Sinusitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Sinusitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Pharyngitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Pharyngitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Pharyngitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Upper Respiratory Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • JAPAN
    • Upper Respiratory Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • CHINA
    • Upper Respiratory Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: China 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: China 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: China 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • EUROPE
    • Upper Respiratory Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Upper Respiratory Tract Infection Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • FRANCE
    • Upper Respiratory Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: France 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: France 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: France 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • GERMANY
    • Upper Respiratory Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Upper Respiratory Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Upper Respiratory Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Upper Respiratory Tract Infection Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Upper Respiratory Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • INDIA
    • Upper Respiratory Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 167: India Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: India 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: India 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: India 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Upper Respiratory Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Upper Respiratory Tract Infection Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Upper Respiratory Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Upper Respiratory Tract Infection Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • AFRICA
    • Upper Respiratory Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제